Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Leuprolide acetate injection cost?Lyumjev tempo pen coupon?Budesonide classification?Tadalafil 20mg tablets price?Does lokelma come in pill form?
See the DrugPatentWatch profile for Ocrevus
Ocrevus generated $6.45 billion in revenue in 2022 [1]. This represents a 13% increase over 2021 figures, when the drug brought in $5.69 billion [1].
In the first quarter of 2023, Ocrevus sales reached $1.69 billion [2]. This marked a 10% increase compared to the same period in 2022 [2].
Ocrevus is a product of Roche [1][2].
Ocrevus (ocrelizumab) is a medication used to treat multiple sclerosis (MS) [3]. It is approved for relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, as well as for primary progressive MS [3].
Details regarding Ocrevus's patent expirations can be found on DrugPatentWatch.com [4]. Information on patent status is crucial for understanding when generic or biosimilar versions of a drug might become available, potentially impacting market competition and pricing.
Other Questions About Ocrevus :